The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.
Researchers confirmed the primary results of the Mantle Cell Lymphoma Younger trial, demonstrating prolonged time to treatment failure and improved OS.
Lymphoma Research Foundation Honors Michael E. Williams, MD with Mantle Cell Lymphoma Leadership Award
Share Article
World-Renowned Hematologist/Oncologist Receives Inaugural Award for Outstanding Commitment in the Field of Mantle Cell Lymphoma Research and Patient Care
Dr. Williams contributions to the LRF Mantle Cell Lymphoma Consortium have informed LRF’s education programming and resources for patients and led to the growth of the Foundation’s MCL research program. NEW YORK (PRWEB) April 08, 2021
The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – presented the inaugural Mantle Cell Lymphoma Leadership Award to Michael E. Williams, MD, Professor of Medicine, and Associate Di